Abstract
The findings and management of a patient with the mitomycin-induced syndrome of thrombotic thrombocytopenic purpura (TTP) is reported. Hyperreactivity of the cytotoxic suppressor T-cell was found. Vincristine and cyclophosphamide reversed the hematologic and renal dysfunction after administration of antiplatelet agents and plasma infusion had failed to do so.
MeSH terms
-
Adenocarcinoma / drug therapy
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / therapeutic use*
-
Doxorubicin / administration & dosage
-
Drug Therapy, Combination
-
Fluorouracil / administration & dosage
-
Humans
-
Male
-
Middle Aged
-
Mitomycin / administration & dosage
-
Mitomycin / adverse effects*
-
Neoplasms, Unknown Primary / drug therapy
-
Plasma
-
Purpura, Thrombotic Thrombocytopenic / chemically induced*
-
Purpura, Thrombotic Thrombocytopenic / drug therapy
-
Purpura, Thrombotic Thrombocytopenic / immunology
-
Purpura, Thrombotic Thrombocytopenic / mortality
-
T-Lymphocytes, Regulatory / pathology
-
Ticlopidine / therapeutic use
-
Vincristine / administration & dosage
-
Vincristine / therapeutic use*
Substances
-
Mitomycin
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Ticlopidine
-
Fluorouracil